Role of p42/p44 mitogen-activated-protein kinase and p21 waf1/cip1 in the regulation of vascular smooth muscle cell proliferation by nitric oxide
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The purpose of this study was to determine the involvement of the p42/p44 mitogen-activated protein kinase (MAPK) pathway and induction of p21 waf1/cip1 in the antiproliferative effects of nitric oxide (NO) on rat aortic smooth muscle cells (RASMC). NO, like α-difluoromethylornithine (DFMO), interferes with cell proliferation by inhibiting ornithine decarboxylase (ODC) and, therefore, polyamine synthesis. S -nitroso- N -acetylpenicillamine or ( Z )-1-[ N -(2-aminoethyl)- N -(2-aminoethyl)-amino]-diazen-1-ium-1,2-diolate inhibited RASMC growth at concentrations as low as 3 μM, and DFMO elicited effects at concentrations of 100 μM or greater. The cytostatic effect of NO and DFMO was prevented by the MAPK kinase 1/2 inhibitors PD 098,059 or U0126. This finding suggests that the p42/p44 MAPK pathway is involved in the inhibition of RASMC proliferation by NO. Western blot analysis revealed that treatment of RASMC with NO or DFMO leads to activation of p42/p44 MAPK and induction of p21 waf1/cip1 . This effect was prevented by MAPK kinase 1/2 inhibitors, suggesting that induction of p21 waf1/cip1 depended on activation of p42/p44. Moreover, activation of p42/p44 and induction of p21 waf1/cip1 were prevented by exogenous putrescine but not ornithine, suggesting this effect was due to the inhibition of ODC by NO or DFMO. Finally, activation of p42/p44 MAPK and induction of p21 waf1/cip1 were cGMP-independent. Neither 1H-(1,2,4)oxadiazolo[4,3-α]quinoxalin-1-one nor zaprinast influenced the cytostatic effect of NO or DFMO or their ability to activate these signal transduction pathways. These observations suggest that inhibition of ODC and accompanying putrescine production are the underlying mechanisms by which NO and DFMO activate the MAPK pathway to promote induction of p21 waf1/cip1 and consequent inhibition of cell proliferation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ignarro, L. J., Lippton, H., Edwards, J. C., Baricos, W. H., Hyman, A. L., Kadowitz, P. J., & Gruetter, C. A. (1981) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32738-2 · Cited by 1,633
Self-citationKeefer, L. K., Nims, R. W., Davies, K. M., & Wink, D. A. (1996) · Methods in Enzymology · doi:10.1016/s0076-6879(96)68030-6 · Cited by 670
Cited by
Polyamine metabolism and cancer
Thomas, T., & Thomas, T. J. (2003) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2003.tb00210.x · Cited by 332
Zuckerbraun, B. S., Shiva, S., Ifedigbo, E., Mathier, M. A., Mollen, K. P., Rao, J., Bauer, P. M., Choi, J. J. W., Curtis, E., Choi, A. M. K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.891077 · Cited by 192
Self-citationNitric oxide, a protective molecule in the cardiovascular system
Lei, J., Vodovotz, Y., Tzeng, E., & Billiar, T. R. (2013) · Nitric Oxide · doi:10.1016/j.niox.2013.09.004 · Cited by 184
Regulation of Vascular Endothelial Growth Factor Synthesis by Nitric Oxide: Facts and Controversies
Dulak, J., & Józkowicz, A. (2003) · Antioxidants & Redox Signaling · doi:10.1089/152308603321223612 · Cited by 130
Alef, M. J., Vallabhaneni, R., Carchman, E., Morris, S. M., Shiva, S., Wang, Y., Kelley, E. E., Tarpey, M. M., Gladwin, M. T., Tzeng, E., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44079 · Cited by 101
Metadata
- Authors
- Bauer, P. M., Buga, G. M., & Ignarro, L. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2001-10-09
- Volume
- 98
- Issue
- 22
- Pages
- 12802-12807
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2045727091
- Cited by
- 66
- References
- 2
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.